NORTH AMERICA ORTHOBIOLOGICS MARKET FORECAST 2017-2025
KEY FINDINGS
The North America orthobiologics market is expected to grow at $5193 million by 2025. The market growth is anticipated at the CAGR of 6.94% in the forecast period. The base year deliberated for the study of the orthobiologics market is 2016. The rise in the orthobiologics material and increasing demand for spinal fusion surgeries are driving the orthobiologics market in North America region.
MARKET INSIGHTS
The North America orthobiologics market is segmented on the basis of product, application, end-user, and geography. The North America market of orthobiologics by product is further segmented into the demineralized bone matrix (DBM), Bone morphogenetic protein (BMP), viscosupplementation, synthetic bone graft substitutes, stem cell therapy and others products market. The application segment is further classified into spinal fusion, trauma repair, and reconstructive surgery, tendon and ligament repair market and other application market. The market by end-user is segmented into hospital market and clinics market. The North America orthobiologics market by geography is further segmented into United States, Canada. Increasing products of orthobiologics leading the growth of orthobilogics market in North America region.
COMPETETIVE INSIGHTS
Major players for the Orthobiologics market are Bioventus, DePuy Inc. (Acquired by Johnson and Johnson), Exatech Inc., Globus Medical Inc., Integra Life sciences Holding Corporation, Johnson& Johnson, Medtronic Inc., Nuvasive Inc., RTI Surgical, Sanofi, Stryker Corporation, Zimmer Biomet Inc., and Mölnlycke Health Care AB.
The North America orthobiologics market is expected to grow at $5193 million by 2025. The market growth is anticipated at the CAGR of 6.94% in the forecast period. The base year deliberated for the study of the orthobiologics market is 2016. The rise in the orthobiologics material and increasing demand for spinal fusion surgeries are driving the orthobiologics market in North America region.
MARKET INSIGHTS
The North America orthobiologics market is segmented on the basis of product, application, end-user, and geography. The North America market of orthobiologics by product is further segmented into the demineralized bone matrix (DBM), Bone morphogenetic protein (BMP), viscosupplementation, synthetic bone graft substitutes, stem cell therapy and others products market. The application segment is further classified into spinal fusion, trauma repair, and reconstructive surgery, tendon and ligament repair market and other application market. The market by end-user is segmented into hospital market and clinics market. The North America orthobiologics market by geography is further segmented into United States, Canada. Increasing products of orthobiologics leading the growth of orthobilogics market in North America region.
COMPETETIVE INSIGHTS
Major players for the Orthobiologics market are Bioventus, DePuy Inc. (Acquired by Johnson and Johnson), Exatech Inc., Globus Medical Inc., Integra Life sciences Holding Corporation, Johnson& Johnson, Medtronic Inc., Nuvasive Inc., RTI Surgical, Sanofi, Stryker Corporation, Zimmer Biomet Inc., and Mölnlycke Health Care AB.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. KEY FINDINGS
4. MARKET OVERVIEW
4.1. MARKET DRIVERS
4.1.1. DEMAND FOR SPINAL FUSION SURGERIES
4.1.2. GROWTH IN STRATEGIC PARTNERSHIPS
4.1.3. INCREASE IN ORTHOBIOLOGICS MATERIAL
4.2. RESTRAINTS
4.2.1. STRINGENT GOVERNMENT POLICIES
4.2.2. POST-SURGERY COMPLICATIONS
4.3. OPPORTUNITIES
4.3.1. BONE REGENERATION TECHNOLOGY
4.3.2. LARGER SPEND ON HEALTHCARE
4.4. CHALLENGES
4.4.1. HIGH COST OF SPINAL FUSION SURGERY
4.4.2. PRODUCT SIDE EFFECTS AND FDA SCRUTINY
4.4.3. POOR PERFORMANCE OF BONE GRAFT SUBSTITUTE
5. SEGMENTATION
5.1. BY PRODUCTS
5.1.1. DEMINERALIZED BONE MATRIX (DBM)
5.1.2. ALLOGRAFT
5.1.3. BONE MORPHOGENETIC PROTEIN (BMP)
5.1.4. VISCOSUPPLEMENTATION
5.1.5. SYNTHETIC BONE GRAFT SUBSTITUTES
5.1.6. STEM CELL THERAPY
5.1.7. OTHERS PRODUCT MARKET
5.2. BY APPLICATION
5.2.1. SPINAL FUSION
5.2.2. TRAUMA REPAIR
5.2.3. RECONSTRUCTIVE SURGERY
5.2.4. TENDON & LIGAMENT REPAIR MARKET
5.2.5. OTHERS APPLICATION MARKET
5.3. BY END-USER
5.3.1. HOSPITALS MARKET
5.3.2. CLINICS MARKET
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCES ANALYSIS
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
6.1.3. BARGAINING POWER OF BUYER
6.1.4. BARGAINING POWER OF SUPPLIER
6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. PESTEL ANALYSIS
6.3. OPPORTUNITY MATRIX
6.4. VALUE CHAIN ANALYSIS
6.5. VENDOR LANDSCAPE
7. NORTH AMERICA ANALYSIS
7.1. NORTH AMERICA ORTHOBIOLOGICS MARKET
7.1.1. UNITED STATES ORTHOBIOLOGICS MARKET
7.1.2. CANADA ORTHOBIOLOGICS MARKET
8. COMPETITIVE LANDSCAPE
8.1. MARKET SHARE ANALYSIS
8.2. MERGERS & ACQUISITIONS
9. COMPANY PROFILE
9.1. BIOVENTUS
9.1.1. OVERVIEW
9.1.2. PRODUCTS PORTFOLIO
9.1.3. STRATEGIC INITIATIVES
9.1.4. SCOT ANALYSIS
9.2. DEPUY INC (ACQUIRED BY JOHNSON AND JOHNSON)
9.2.1. OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. STRATEGIC INITIATIVES
9.2.4. SCOT ANALYSIS
9.2.5. STRATEGIC ANALYSIS
9.3. EXATECH INC
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. SCOT
9.3.4. STRATEGIC ANALYSIS
9.4. GLOBUS MEDICAL INC
9.4.1. OVERVIEW
9.4.2. PRODUCT PORTFOLIO
9.4.3. STRATEGIC INITIATIVES
9.4.4. SCOT
9.4.5. STRATEGIC ANALYSIS
9.5. INTEGRA LIFESCIENCES HOLDING CORPORATION
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. STRATEGIC INITIATIVES
9.5.4. SCOT ANALYSIS
9.5.5. STRATEGIC ANALYSIS
9.6. JOHNSON & JOHNSON
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. STRATEGIC INITIATIVES
9.6.4. SWOT ANALYSIS
9.7. MEDTRONIC INC
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. STRATEGIC INITIATIVES
9.7.4. SCOT
9.8. NUVASIVE INC
9.8.1. OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. STRATEGIC INITIATIVES
9.8.4. SCOT ANALYSIS
9.8.5. STRATEGIC ANALYSIS
9.9. RTI SURGICAL
9.9.1. OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. STRATEGIC INITIATIVES
9.9.4. SCOT ANALYSIS
9.10. SANOFI
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. STRATEGIC INITIATIVES
9.10.4. SCOT ANALYSIS
9.11. STRYKER CORPORATION
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. STRATEGIC INITIATIVES
9.11.4. SCOT ANALYSIS
9.11.5. STRATEGIC ANALYSIS
9.12. ZIMMER BIOMET INC
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. STRATEGIC INITIATIVES
9.12.4. SCOT ANALYSIS
9.12.5. STRATEGIC ANALYSIS
9.13. MÖLNLYCKE HEALTH CARE AB
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. STRATEGIC INITIATIVES
9.13.4. SCOT ANALYSIS
TABLE LIST
TABLE 1 OLDER POPULATION BY AGE GROUP: 1900 TO 2050
TABLE 2 FINANCING FOR ORTHOBIOLOGICS ADVANCEMENT
TABLE 3 POST-SURGERY COMPLICATION
TABLE 4 NORTH AMERICA ORTHOBIOLOGICS MARKET BY PRODUCTS 2017-2025 ($ MILLIONS)
TABLE 5 DEMINERALIZED BONE MATRIX ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
TABLE 6 ALLOGRAFT ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
TABLE 7 BONE MORPHOGENETIC PROTEIN (BMP) ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
TABLE 8 VISCOSUPPLEMENTATION MARKET 2017-2025 ($ MILLIONS)
TABLE 9 SYNTHETIC BONE GRAFT MARKET 2017-2025 ($ MILLIONS)
TABLE 10 STEM CELL THERAPY MARKET 2017-2025 ($ MILLIONS)
TABLE 11 OTHER PRODUCTS MARKET 2017-2025 ($ MILLIONS)
TABLE 12 NORTH AMERICA ORTHOBIOLOGICS MARKET BY APPLICATION 2017-2025 ($ MILLIONS)
TABLE 13 SPINAL FUSION MARKET 2017-2025 ($ MILLIONS)
TABLE 14 TRAUMA REPAIR MARKET 2017-2025 ($ MILLIONS)
TABLE 15 RECONSTRUCTIVE SURGERY MARKET 2017-2025 ($ MILLIONS)
TABLE 16 TENDON & LIGAMENT ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
TABLE 17 OTHER APPLICATIONS ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
TABLE 18 NORTH AMERICA ORTHOBIOLOGICS MARKET BY END-USER, 2017-2025 ($ MILLION)
TABLE 19 HOSPITAL ORTHOBIOLOGICS MARKET, 2017-2025 ($ MILLIONS)
TABLE 20 ORTHOBIOLOGICS CLINICS MARKET 2017-2025 ($ MILLIONS)
TABLE 21 NORTH AMERICA ORTHOBIOLOGICS MARKET, BY COUNTRY 2017-2025 ($ MILLION)
FIGURES LIST
FIGURE 1 INCREASING DEMAND OF MINIMAL INVASIVE TECHNOLOGIES 2010-2025 ($ MILLION)
FIGURE 2 DEMINERALIZED BONE MATRIX ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 3 ALLOGRAFT ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 4 BONE MORPHOGENIC PROTEIN (BMP) ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 5 VISCOSUPPLEMENTATION ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 6 SYNTHETIC BONE GRAFT ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 7 STEM CELL THERAPY ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 8 NORTH AMERICA OTHER PRODUCTS MARKET 2017-2025 ($ MILLION)
FIGURE 9 SPINAL FUSION ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 10 TRAUMA REPAIR ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 11 RECONSTRUCTIVE SURGERY ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 12 TENDON & LIGAMENT ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 13 OTHER APPLICATIONS ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 14 COST OF KNEE REPLACEMENT IN DEVELOPING COUNTRIES IN 2017
FIGURE 15 ORTHOBIOLOGICS HOSPITAL MARKET 2017-2025 ($ MILLIONS)
FIGURE 16 ORTHOBIOLOGICS CLINICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 17 NORTH AMERICA POPULATION AGES 65 AND ABOVE (% OF TOTAL) BY COUNTRIES 2016
FIGURE 18 NORTH AMERICA ORTHOBIOLOGICS MARKET BY COUNTRY 2016 & 2025(% SHARE)
FIGURE 19 UNITED STATES (U.S.) ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLION)
FIGURE 20 HEALTHCARE EXPENDITURE IN THE U.S. 2014 & 2025 (% OF GDP)
FIGURE 21 CANADA ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLION)
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. KEY FINDINGS
4. MARKET OVERVIEW
4.1. MARKET DRIVERS
4.1.1. DEMAND FOR SPINAL FUSION SURGERIES
4.1.2. GROWTH IN STRATEGIC PARTNERSHIPS
4.1.3. INCREASE IN ORTHOBIOLOGICS MATERIAL
4.2. RESTRAINTS
4.2.1. STRINGENT GOVERNMENT POLICIES
4.2.2. POST-SURGERY COMPLICATIONS
4.3. OPPORTUNITIES
4.3.1. BONE REGENERATION TECHNOLOGY
4.3.2. LARGER SPEND ON HEALTHCARE
4.4. CHALLENGES
4.4.1. HIGH COST OF SPINAL FUSION SURGERY
4.4.2. PRODUCT SIDE EFFECTS AND FDA SCRUTINY
4.4.3. POOR PERFORMANCE OF BONE GRAFT SUBSTITUTE
5. SEGMENTATION
5.1. BY PRODUCTS
5.1.1. DEMINERALIZED BONE MATRIX (DBM)
5.1.2. ALLOGRAFT
5.1.3. BONE MORPHOGENETIC PROTEIN (BMP)
5.1.4. VISCOSUPPLEMENTATION
5.1.5. SYNTHETIC BONE GRAFT SUBSTITUTES
5.1.6. STEM CELL THERAPY
5.1.7. OTHERS PRODUCT MARKET
5.2. BY APPLICATION
5.2.1. SPINAL FUSION
5.2.2. TRAUMA REPAIR
5.2.3. RECONSTRUCTIVE SURGERY
5.2.4. TENDON & LIGAMENT REPAIR MARKET
5.2.5. OTHERS APPLICATION MARKET
5.3. BY END-USER
5.3.1. HOSPITALS MARKET
5.3.2. CLINICS MARKET
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCES ANALYSIS
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
6.1.3. BARGAINING POWER OF BUYER
6.1.4. BARGAINING POWER OF SUPPLIER
6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. PESTEL ANALYSIS
6.3. OPPORTUNITY MATRIX
6.4. VALUE CHAIN ANALYSIS
6.5. VENDOR LANDSCAPE
7. NORTH AMERICA ANALYSIS
7.1. NORTH AMERICA ORTHOBIOLOGICS MARKET
7.1.1. UNITED STATES ORTHOBIOLOGICS MARKET
7.1.2. CANADA ORTHOBIOLOGICS MARKET
8. COMPETITIVE LANDSCAPE
8.1. MARKET SHARE ANALYSIS
8.2. MERGERS & ACQUISITIONS
9. COMPANY PROFILE
9.1. BIOVENTUS
9.1.1. OVERVIEW
9.1.2. PRODUCTS PORTFOLIO
9.1.3. STRATEGIC INITIATIVES
9.1.4. SCOT ANALYSIS
9.2. DEPUY INC (ACQUIRED BY JOHNSON AND JOHNSON)
9.2.1. OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. STRATEGIC INITIATIVES
9.2.4. SCOT ANALYSIS
9.2.5. STRATEGIC ANALYSIS
9.3. EXATECH INC
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. SCOT
9.3.4. STRATEGIC ANALYSIS
9.4. GLOBUS MEDICAL INC
9.4.1. OVERVIEW
9.4.2. PRODUCT PORTFOLIO
9.4.3. STRATEGIC INITIATIVES
9.4.4. SCOT
9.4.5. STRATEGIC ANALYSIS
9.5. INTEGRA LIFESCIENCES HOLDING CORPORATION
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. STRATEGIC INITIATIVES
9.5.4. SCOT ANALYSIS
9.5.5. STRATEGIC ANALYSIS
9.6. JOHNSON & JOHNSON
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. STRATEGIC INITIATIVES
9.6.4. SWOT ANALYSIS
9.7. MEDTRONIC INC
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. STRATEGIC INITIATIVES
9.7.4. SCOT
9.8. NUVASIVE INC
9.8.1. OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. STRATEGIC INITIATIVES
9.8.4. SCOT ANALYSIS
9.8.5. STRATEGIC ANALYSIS
9.9. RTI SURGICAL
9.9.1. OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. STRATEGIC INITIATIVES
9.9.4. SCOT ANALYSIS
9.10. SANOFI
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. STRATEGIC INITIATIVES
9.10.4. SCOT ANALYSIS
9.11. STRYKER CORPORATION
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. STRATEGIC INITIATIVES
9.11.4. SCOT ANALYSIS
9.11.5. STRATEGIC ANALYSIS
9.12. ZIMMER BIOMET INC
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. STRATEGIC INITIATIVES
9.12.4. SCOT ANALYSIS
9.12.5. STRATEGIC ANALYSIS
9.13. MÖLNLYCKE HEALTH CARE AB
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. STRATEGIC INITIATIVES
9.13.4. SCOT ANALYSIS
TABLE LIST
TABLE 1 OLDER POPULATION BY AGE GROUP: 1900 TO 2050
TABLE 2 FINANCING FOR ORTHOBIOLOGICS ADVANCEMENT
TABLE 3 POST-SURGERY COMPLICATION
TABLE 4 NORTH AMERICA ORTHOBIOLOGICS MARKET BY PRODUCTS 2017-2025 ($ MILLIONS)
TABLE 5 DEMINERALIZED BONE MATRIX ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
TABLE 6 ALLOGRAFT ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
TABLE 7 BONE MORPHOGENETIC PROTEIN (BMP) ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
TABLE 8 VISCOSUPPLEMENTATION MARKET 2017-2025 ($ MILLIONS)
TABLE 9 SYNTHETIC BONE GRAFT MARKET 2017-2025 ($ MILLIONS)
TABLE 10 STEM CELL THERAPY MARKET 2017-2025 ($ MILLIONS)
TABLE 11 OTHER PRODUCTS MARKET 2017-2025 ($ MILLIONS)
TABLE 12 NORTH AMERICA ORTHOBIOLOGICS MARKET BY APPLICATION 2017-2025 ($ MILLIONS)
TABLE 13 SPINAL FUSION MARKET 2017-2025 ($ MILLIONS)
TABLE 14 TRAUMA REPAIR MARKET 2017-2025 ($ MILLIONS)
TABLE 15 RECONSTRUCTIVE SURGERY MARKET 2017-2025 ($ MILLIONS)
TABLE 16 TENDON & LIGAMENT ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
TABLE 17 OTHER APPLICATIONS ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
TABLE 18 NORTH AMERICA ORTHOBIOLOGICS MARKET BY END-USER, 2017-2025 ($ MILLION)
TABLE 19 HOSPITAL ORTHOBIOLOGICS MARKET, 2017-2025 ($ MILLIONS)
TABLE 20 ORTHOBIOLOGICS CLINICS MARKET 2017-2025 ($ MILLIONS)
TABLE 21 NORTH AMERICA ORTHOBIOLOGICS MARKET, BY COUNTRY 2017-2025 ($ MILLION)
FIGURES LIST
FIGURE 1 INCREASING DEMAND OF MINIMAL INVASIVE TECHNOLOGIES 2010-2025 ($ MILLION)
FIGURE 2 DEMINERALIZED BONE MATRIX ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 3 ALLOGRAFT ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 4 BONE MORPHOGENIC PROTEIN (BMP) ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 5 VISCOSUPPLEMENTATION ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 6 SYNTHETIC BONE GRAFT ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 7 STEM CELL THERAPY ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 8 NORTH AMERICA OTHER PRODUCTS MARKET 2017-2025 ($ MILLION)
FIGURE 9 SPINAL FUSION ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 10 TRAUMA REPAIR ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 11 RECONSTRUCTIVE SURGERY ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 12 TENDON & LIGAMENT ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 13 OTHER APPLICATIONS ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 14 COST OF KNEE REPLACEMENT IN DEVELOPING COUNTRIES IN 2017
FIGURE 15 ORTHOBIOLOGICS HOSPITAL MARKET 2017-2025 ($ MILLIONS)
FIGURE 16 ORTHOBIOLOGICS CLINICS MARKET 2017-2025 ($ MILLIONS)
FIGURE 17 NORTH AMERICA POPULATION AGES 65 AND ABOVE (% OF TOTAL) BY COUNTRIES 2016
FIGURE 18 NORTH AMERICA ORTHOBIOLOGICS MARKET BY COUNTRY 2016 & 2025(% SHARE)
FIGURE 19 UNITED STATES (U.S.) ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLION)
FIGURE 20 HEALTHCARE EXPENDITURE IN THE U.S. 2014 & 2025 (% OF GDP)
FIGURE 21 CANADA ORTHOBIOLOGICS MARKET 2017-2025 ($ MILLION)
